Duloxetine: sexual effects and PE research

Duloxetine is an SNRI antidepressant with licensed uses that include depression, anxiety and certain pain conditions in the UK reference information. It appears here because researchers have studied it for premature ejaculation (PE), and because Malegra DXT is historically listed with sildenafil plus duloxetine. Those are distinct evidence questions.

Key points

• PE is an off-label research context in the checked UK label.
• A small study found an improvement, but substantial patient loss limits confidence.
• Benefit during daily treatment did not establish lasting benefit after stopping it.
• The study did not test Malegra DXT or an occasional fixed-combination tablet.
• Formulation, sexual adverse effects, blood pressure and discontinuation matter in a clinical review.

What the 2023 study found

A single-centre placebo-controlled crossover study enrolled 100 men with lifelong or acquired PE. Thirty-two were lost to follow-up, leaving 68 in the reported analysis. Participants received duloxetine and placebo in different periods, separated by a washout. The treatment period began with daily 30 mg and then used a tapering schedule; this is a description of the research, not an individual regimen recommendation.

Median measured time from vaginal penetration to ejaculation was 180 seconds after duloxetine versus 60 seconds after placebo. Questionnaire measures of PE and sexual quality of life also improved. The full report states that timing and PE questionnaire scores returned toward baseline after treatment was discontinued.

A crossover design lets the same person contribute observations under both treatments. It also makes treatment order, washout and withdrawals important to interpretation. Losing almost a third of those enrolled reduces confidence that the remaining participants represent everyone who started. The study was short, used one centre and did not compare duloxetine directly with established active PE treatments.

The findings are a reason for further research and a careful clinical discussion. They do not establish superiority over dapoxetine, long-term safety in PE or rapid benefit from a seller’s ED/PE combination.

Why the formulation cannot be skipped

The UK reference product is a gastro-resistant capsule. Gastro-resistant or delayed-release formulations control where the medicine is released. The physical form, release design and matching evidence therefore belong in the assessment of a combination product.

It would be too broad to claim that no duloxetine tablet can exist anywhere. Equally, a tablet marketed with duloxetine cannot be assumed equivalent to the reference capsule without formulation-specific evidence. The small PE trial does not settle that manufacturing question or validate the release design of Malegra DXT.

Desired delay can coexist with unwanted sexual effects

The reference information includes sexual dysfunction such as reduced desire, erection difficulties and orgasm or ejaculation changes. These can be relevant even when ejaculation delay is the intended treatment goal. Reports of persistent sexual symptoms after SSRI/SNRI discontinuation are also noted, without giving a reliable frequency for a PE-treatment population.

Common adverse effects include nausea, headache, dry mouth, sleepiness and dizziness. Duloxetine can affect blood pressure and has important liver, kidney and serotonergic interaction considerations. Another antidepressant, certain pain medicines or a second product containing duloxetine may change the risk assessment.

Starting and stopping require a plan

Abrupt discontinuation can cause withdrawal symptoms. The prescribing team should guide changes, rather than a person copying the research schedule or replacing an existing antidepressant with an ED/PE tablet. Mood changes and new sexual symptoms also deserve follow-up.

The clinical question is whether the proposed treatment addresses the person’s main concern, has an acceptable formulation and evidence base, and fits the rest of their medicines. A historical product catalogue association answers only part of that question.

Sources

3 sources

Checked October 4, 2026.

1. Duloxetine UK product information — emc
2. Daily duloxetine PE crossover trial — Basic and Clinical Andrology, 2023
3. Duloxetine PE trial full text — Europe PMC